Skip to main content

An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.

  • NCT00002194
  • PHASE1
  • INTERVENTIONAL

Last updated: 2005-06-24

Purpose of  Trial

The study is conducted in two separate groups. Patients in Group I receive clarithromycin orally for 32 days and nevirapine orally for 28 days.

Patients in Group II receive erythromycin intravenously on days 0, 14, 28, and 43 and nevirapine orally for 28 days.


This study is for people with

HIV Infections


Interventions being studied

Erythromycin

Nevirapine

Clarithromycin

Register to Save
ELIGIBILITY

Gender: ALL

Age: 18+

Healthy Volunteers: No

Location
Miami

South Florida Bioavailability Clinic


Florida, 331813405, United States
Primary Contact(s)

Boehringer Ingelheim

Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at ClinicalTrials.gov

Back to Results New Search